Skip to Content
Reach blood sugar goals with long-acting insulin. Go >

Welchol (colesevelam) Disease Interactions

There are 5 disease interactions with Welchol (colesevelam):

Major

Colesevelam (Includes Welchol) ↔ Diabetic Ketoacidosis

Severe Potential Hazard, Moderate plausibility

Applies to: Diabetes Type 1, Diabetic Ketoacidosis, Diabetic Ketoacidosis (in DM Type I), Diabetic Ketoacidosis (in DM Type II)

Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.

Major

Colesevelam (Includes Welchol) ↔ Tg

Severe Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia, Pancreatitis

The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL. Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations. Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter. Caution should be exercised when treating patients with TG levels greater than 300 mg/dL. Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.

Moderate

Bile Acid Sequestrants (Includes Welchol) ↔ Pku

Moderate Potential Hazard, Moderate plausibility

Applies to: Phenylketonuria

Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose. Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose. WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics). Regular Colestid, Questran and LoCholest do not contain phenylalanine.

References

  1. "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc, Chestnut Ridge, NY.
  2. "Product Information. Questran Light (cholestyramine)." Bristol-Myers Squibb, Princeton, NJ.
  3. "Product Information. Colestid (colestipol HCI)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Colesevelam (Includes Welchol) ↔ Gastrointestinal Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Obstruction, Gastroparesis, Dysphagia

The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction. Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction. Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.

Moderate

Colesevelam (Includes Welchol) ↔ Malabsorption Syndromes

Moderate Potential Hazard, Moderate plausibility

Applies to: Malabsorption Syndrome, Vitamin A Deficiency, Vitamin D Deficiency, Vitamin K Deficiency

Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K. Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins. The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.

Welchol (colesevelam) drug Interactions

There are 145 drug interactions with Welchol (colesevelam)

Welchol (colesevelam) alcohol/food Interactions

There are 2 alcohol/food interactions with Welchol (colesevelam)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide